Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


TransMedics to Participate in the Canaccord Genuity Virtual MedTech,


PR Newswire | Nov 4, 2021 04:05PM EDT

Diagnostics, and Digital Health & Services Forum

11/04 15:05 CDT

TransMedics to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum ANDOVER, Mass., Nov. 4, 2021

ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on Thursday, November 18, 2021.

For more information on the company, please visit https://investors.transmedics.com/.

About TransMedics Group, Inc.TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:Brian Johnston631-807-1986Investors@transmedics.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-canaccord-genuity-virtual-medtech-diagnostics-and-digital-health--services-forum-301415984.html

SOURCE TransMedics Group, Inc.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC